Spontaneous growth in idiopathic short stature. European Study Group.

Rekers-Mombarg, L.T.M.; Wit, J. M.; Massa, Guy; Ranke, Michael B.; Buckler, John; Butenandt, O; Chaussain, J. L.; Frisch, H; Leiberman, Esther

doi:10.1136/adc.75.3.175

Cited by 49 publications

(44 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A similar pattern was seen for SH and LL SDS. This result confirms our and others' earlier findings (28,29). It also shows that HSDS for BA in young children severely over-predicts AH.…”

Section: Discussionsupporting

confidence: 82%

High-dose GH treatment limited to the prepubertal period in young children with idiopathic short stature does not increase adult height

Gool

Kamp

Odink

et al. 2010

European Journal of Endocrinology

Self Cite

View full text Add to dashboard Cite

Objective: To assess the long-term effect of prepubertal high-dose GH treatment on growth in children with idiopathic short stature (ISS). Design and methods: Forty children with no signs of puberty, age at start 4-8 years (girls) or 4-10 years (boys), height SDS !K2.0 SDS, and birth length OK2.0 SDS, were randomly allocated to receive GH at a dose of 2 mg/m 2 per day (equivalent to 75 mg/kg per day at start and 64 mg/kg per day at stop) until the onset of puberty for at least 2 years (preceded by two 3-month periods of treatment with low or intermediate doses of GH separated by two washout periods of 3 months) or no treatment. In 28 cases, adult height (AH) was assessed at a mean (S.D.) age of 20.4 (2.3) years. Results: GH-treated children (mean treatment period on high-dose GH 2.3 years (range 1.2-5.0 years)) showed an increased mean height SDS at discontinuation of the treatment compared with the controls (K1.3 (0.8) SDS versus K2.6 (0.8) SDS respectively). However, bone maturation was significantly accelerated in the GH-treated group compared with the controls (1.6 (0.4) versus 1.0 (0.2) years per year, respectively), and pubertal onset tended to advance. After an untreated interval of 3-12 years, AH was K2.1 (0.7) and K1.9 (0.6) in the GH-treated and control groups respectively. Age was a positive predictor of adult height gain. Conclusion: High-dose GH treatment restricted to the prepubertal period in young ISS children augments height gain during treatment, but accelerates bone maturation, resulting in a similar adult height compared with the untreated controls.

show abstract

“…A similar pattern was seen for SH and LL SDS. This result confirms our and others' earlier findings (28,29). It also shows that HSDS for BA in young children severely over-predicts AH.…”

Section: Discussionsupporting

confidence: 82%

High-dose GH treatment limited to the prepubertal period in young children with idiopathic short stature does not increase adult height

Gool

Kamp

Odink

et al. 2010

European Journal of Endocrinology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Even in ISS good responders to GH treatment seem to exist [9, 13], and the as yet poorly recognizable children with partial GHD may also have a good responsiveness. On the other hand, a large proportion of untreated ISS children seem to reach their genetic growth potential without GH treatment [9, 30]. We suggest that a tool should be developed for short children with maximum GH peaks >10 mU/l that identifies those who are most likely to benefit from GH treatment.…”

Section: Discussionmentioning

confidence: 99%

Growth Response to Recombinant Human Growth Hormone (GH) in Children with Idiopathic Growth Retardation by Level of Maximum GH Peak during GH Stimulation Tests

Broeck¹,

Arends

Hokken-Koelega

2000

Horm Res Paediatr

View full text Add to dashboard Cite

Due to their lack of reproducibility, it is unlikely that GH stimulation tests can provide reliable diagnostic information to distinguish partial isolated GH deficiency (GHD) from idiopathic short stature (ISS). We hypothesized that the classical distinction between these groups, essentially based on stimulatory GH peaks, is artificial and that, as a consequence, the average response to GH treatment will not be different between them. The hypothesized lack of prognostic validity of stimulatory GH peaks was studied in 435 prepubertal children with nonorganic growth retardation. Children were categorized as ‘severe GHD’, ‘partial GHD’ or ‘ISS’, if the maximum rise in their serum GH during two GH stimulation tests was 0– 10 mU/l, 10–20 mU/l, or >20 mU/l, respectively. Children with ‘partial GHD’ had short-term (1- and 2-year) and long-term (till final adult height) growth responses similar to those of children with ISS, significantly lower than the response seen in children with ‘severe GHD’. In children with stimulatory GH peaks >10 mU/l, including those currently considered partially GH deficient, the maximum GH peak was not a significant determinant of growth response in the short or the long term. In conclusion, ‘partial GHD’ is ill defined and cannot be distinguished from ISS based on the currently applied auxological or GH stimulation test criteria alone. More research is required for better identification of (all) children who will respond to GH treatment, whether or not GH deficient.

show abstract

“…However, according to several papers reported height was as reliable as measured in the clinic [9, 23, 24]. It is also possible that some of our patients were measured at near-final rather than final height.…”

Section: Discussionmentioning

confidence: 62%

“…Crowne et al [21] suggested that the greater the bone age retardation, the less accurate the prediction methods. The RWT method analyses the greatest number of parameters potentially influencing the final height and most authors recognize it as the most accurate [11, 19, 24]. …”

Section: Discussionmentioning

confidence: 99%

Are Short Boys with Constitutional Delay of Growth and Puberty Candidates for rGH Therapy according to FDA Recommendations?

2006

View full text Add to dashboard Cite

Background/Aims: According to FDA-approved guidelines, boys whose height predictions fall to 160 cm or less are considered for treatment with recombinant growth hormone (rGH). The aim of this study was to analyze the value of different height prediction methods by accurately identifying those boys with constitutional delay of growth and puberty (CDGP) in whom final height (FH) prognosis was poor (≤160 cm) and who might therefore be candidates for this treatment modality. Methods: In 69 boys with CDGP diagnosed at a mean age of 14.9 ±1.2 years, FH prediction was calculated by means of Bayley-Pinneau (BP), Roche-Wainer-Tissen (RWT), Tanner-Whitehouse II (TWII) and target height (TH) methods. At the age of 22.6 ± 3.5 years their height was remeasured and the accuracy of height prediction was analyzed. Results: In 6 men (8.7%) measured FH was ≤160 cm. Depending on the prediction method, different individual patients within the 14- to 16-year age range would have been candidates for rGH treatment. The BP method would have recruited 8 subjects of whom only 3 had FH ≤160 cm (sensitivity 50%, specificity 92%). The RWT and TW II methods identified only one recruit, and this patient did achieve FH ≤160 cm (sensitivity 17%, specificity 100%). None of the 8 subjects with FH ≤160 cm would have qualified for GH treatment using the TH method. In three boys none of the four methods predicted their final height ≤160 cm. Conclusion: Although some boys with CDGP may be considered the candidates for rGH treatment according to FDA recommendations, none of the available methods of prediction are sufficiently sensitive to reliably recruit 14- to 16-year-old boys whose final height will fall at or below 160 cm.

show abstract

Spontaneous growth in idiopathic short stature. European Study Group.

Cited by 49 publications

References 24 publications

High-dose GH treatment limited to the prepubertal period in young children with idiopathic short stature does not increase adult height

High-dose GH treatment limited to the prepubertal period in young children with idiopathic short stature does not increase adult height

Growth Response to Recombinant Human Growth Hormone (GH) in Children with Idiopathic Growth Retardation by Level of Maximum GH Peak during GH Stimulation Tests

Are Short Boys with Constitutional Delay of Growth and Puberty Candidates for rGH Therapy according to FDA Recommendations?

Contact Info

Product

Resources

About